Journal of Atherosclerosis and Thrombosis,
Journal Year:
2016,
Volume and Issue:
23(12), P. 1355 - 1364
Published: Jan. 1, 2016
Aim:
Low-density
lipoprotein
cholesterol
(LDL-C)
is
routinely
estimated
using
the
Friedewald
equation
[LDL-C(F)].
A
novel
method
for
LDL-C
[LDL-C(M)]
estimation
recently
proposed
by
Martin
et
al.
was
reported
to
be
more
accurate
than
formula
in
subjects
United
States.
The
validity
of
LDL-C(M)
different
races
and
patients
with
diabetes
mellitus
(DM)
has
not
been
elucidated.
purpose
this
study
validate
estimates
Japanese
population
type
2
DM
comparing
LDL-C(F)
directly
measured
[LDL-C(D)].
Circulation Journal,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 13, 2024
Aggressive
lipid-lowering
therapy
is
important
for
secondary
prevention
of
acute
myocardial
infarction
(AMI).
The
recommended
target
low-density
lipoprotein
cholesterol
(LDL-C)
<70
mg/dL
often
not
achieved.
To
address
this
gap,
we
implemented
a
clinical
pathway
in
all
hospitals
that
perform
percutaneous
coronary
interventions
(PCI)
with
primary
care
physicians
Nagasaki
and
aimed
to
validate
the
effectiveness
an
setting.
Circulation Journal,
Journal Year:
2024,
Volume and Issue:
88(10), P. 1629 - 1636
Published: Feb. 29, 2024
Real-world
utilization
data
for
evolocumab,
the
first
proprotein
convertase
subtilisin/kexin
type
9
(PCSK9)
inhibitor
to
be
introduced
in
Japan
2016,
date
are
limited.
This
study
aimed
clarify
current
real-world
patient
user
profiles
of
evolocumab
based
on
large-scale
health
claims
data.
Journal of Atherosclerosis and Thrombosis,
Journal Year:
2024,
Volume and Issue:
31(11), P. 1517 - 1538
Published: April 12, 2024
Aims:
Pemafibrate,
a
selective
peroxisome
proliferator-activated
receptor
α
modulator
that
lowers
serum
triglyceride
levels
and
increases
high-density
lipoprotein
cholesterol
levels,
is
approved
for
treating
dyslipidemia
as
twice-daily
immediate-release
(IR)
tablets.
A
once-daily
extended-release
(XR)
tablet
has
also
been
developed.
We
aimed
to
confirm
the
non-inferiority
of
XR
(0.2
or
0.4
mg/day;
once
daily)
IR
twice
in
lowering
patients
with
hypertriglyceridemia.
Journal of Atherosclerosis and Thrombosis,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Long-term
exposure
to
fine
particulate
matter
(PM2.5)
is
causally
associated
with
mortality
and
cardiovascular
disease.
However,
in
terms
of
cause-specific
outcomes,
there
are
fewer
studies
about
stroke
than
coronary
heart
disease,
particularly
Asia.
Furthermore,
remains
uncertainty
regarding
the
PM2.5-respiratory
disease
association.
We
examined
whether
long-term
PM2.5
all-cause,
respiratory
Japan.
used
data
46,974
participants
(19,707
men;
27,267
women),
who
were
enrolled
2009
followed
up
until
2019,
a
community-based
prospective
cohort
study
(the
second
Ibaraki
Prefectural
Health
Study).
estimated
concentrations
using
inverse
distance
weighing
methods
based
on
ambient
air
monitoring
data,
assigned
each
participant
administrative
area
level
concentrations.
A
Cox
proportional
hazard
model
was
applied
estimate
ratios
(HRs)
95%
confidence
intervals
(CIs)
mortality.
During
average
follow-up
10
years,
we
confirmed
2,789
all-cause
deaths.
All
outcomes
including
did
not
significantly
increase
as
concentration
increased.
For
non-malignant
mortality,
multivariable
adjusted
HR
per
1
µg/m3
1.09
(95%
CI
=
0.97-1.23).
In
this
population
exposed
at
8.3-13.1
µg/m3,
no
evidence
that
had
adverse
effects
Weak
positive
association
observed
for
needs
further
other
populations.
Journal of Atherosclerosis and Thrombosis,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Long-term
safety
and
efficacy
of
pemafibrate
once-daily
extended-release
(XR)
tablets,
taken
in
morning
or
evening,
were
evaluated
dyslipidemic
patients
with
high
triglycerides
(TG).
In
this
multicenter,
randomized,
open-label,
parallel-group,
phase
3
long-term
study,
TG
randomly
assigned
to
evening
administration
XR
for
52
weeks.
The
dose
was
started
at
0.2
mg/day
increased
0.4
having
fasting
serum
≥
150mg/dL
during
treatment.
primary
endpoint
percent
change
TG.
study
enrolled
121
patients,
assigning
61
60
administration.
population
included
71.1%
males.
Mean
age
58.5±11.1
(mean±SD)
years,
body
mass
index
27.7±4.3
kg/m2,
264.0±109.2
mg/dL.
Fasting
decreased
significantly
from
baseline
weeks
among
overall
the
groups
(-45.7%,
-44.8%,
-46.6%,
respectively,
p＜0.001
vs.
baseline).
difference
least-squares
mean
between
3.0%,
not
statistically
significant.
82
(44
38
evening),
57.3%
(95%CI
45.9,
68.2)
achieving
＜150
Adverse
events
occurred
83.5%
adverse
drug
reactions
19.0%
but
no
notable
problems.
Long-term,
effective
safe
provided
favorable
TG-lowering
effects
regardless
administration,
increase
proved
initially
inadequate
response.
